TrialBlood cancer journal2022

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.

Tomáš Stopka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.